pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Exdensur
drug
save

depemokimab

Marketedupdated 3mo ago
by $GSK GSK plc
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • drugEXDENSUR4 co-mentions · 1 sources
  • tagApproval4 co-mentions · 1 sources
  • companyGlaxoSmithKline LLC2 co-mentions · 1 sources

indications

investigational
Asthma

all catalysts(1)

approval · 1
Dec 16, 2025
approval
8mo ago
EXDENSUR (DEPEMOKIMAB-ULAA) — FDA approval
depemokimab
→

Trials studying depemokimab

  • phase4Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)not yet recruitingn=28
  • phase3Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)active not recruitingn=163
  • phase3Depemokimab Asthma Imaging and Bronchoscopy Sub-Studyrecruitingn=150
  • phase3Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)recruitingn=960
  • phase3A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthmanot yet recruitingn=456
  • phase3An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)completedn=641
  • phase3Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polypscompletedn=276
  • phase3Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trialrecruitingn=123
more trials →

News(0)

no news has mentioned this drug yet

brand
Exdensur
generic
depemokimab-ulaa
indication
Nasal Polyps (Nasal Polyposis)
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 27m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?